Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
Angela Rivers, MD, PhD
Researcher Assistant Professor
Division of Hematology/Oncology
University of Illinois College of Medicine
Outpatient Care Center, Suite 2E
1801 West Taylor Street
Chicago, Illinois, United States
Dr. Rivers is the Director at Sickle Cell Transition Adolescent-Adult Readiness Clinic (STAR) program. Her research interests focus on the Adeno Associated Virus as a vector for gene therapy in sickle cell disease. She has received NIH K08 funding for lab research inducers of fetal hemoglobin. The research (K01 HL103172-01, NIH/ NIHLBI) led by Dr. Rivers focuses on AAV capsid engineering to facilitate expression of therapeutic levels of beta-globin in mouse hematopoietic stem cells. Because everyone is not a candidate for transplantation, successful treatment for sickle cell disease needs to include the development of therapeutic options beside hydroxyurea. Under the mentorship of Dr. Don Lavelle and Dr. Joseph De Simone at the University of Illinois Chicago, the research of Dr. Rivers also focuses on the possible phenotypic correction of sickle disease by induction of hemoglobin F with the combination treatment of Decitabine and novel drugs.
Representative Publications:
+myBinderRelated Content
-
Webinar Series: Sickle Cell Science: Path to Progress – Bone Marrow Transplants, Other Therapies, and Sickle C...To commemorate Sickle Cell Awareness Mon...
-
Iris Buchanan-Perry, MD, MSc, FAAPDr. Buchanan serves as a Clinical Instru...
-
Timothy Lee McCavit, MDTimothy L. McCavit earned a MS in molecu...
-
Spearheading change on World Sickle Cell DayThis year on World Sickle Cell Day, a ne...
-
Children’s Hospital of WisconsinThe Sickle Cell Research Program at Chil...
-
Decreased hospital readmissions for vaso occlusive crisis with implementation of a Sickle Cell Pain Action Plan (SPA...Vaso occlusive crisis (VOC) is the most ...
-
GlycoMimetics Announces Pricing of Public Offering of Common StockGlycoMimetics, Inc. (NASDAQ: GLYC), a cl...
